<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (TNF-alpha) is believed to play a major role in apoptotic <z:hpo ids='HP_0011420'>death</z:hpo> of bone marrow cells in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We explored the efficacy and safety profile of infliximab chimaeric anti-TNF-alpha monoclonal antibody treatment in two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="2" pm="."><plain>They both had low-/intermediate-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, isolated <z:hpo ids='HP_0001903'>anaemia</z:hpo> and elevated circulating levels of TNF-alpha </plain></SENT>
<SENT sid="3" pm="."><plain>Infliximab produced no adverse side-effects and resulted in sustained erythroid responses, one major and one minor </plain></SENT>
<SENT sid="4" pm="."><plain>Laboratory studies indicated a remarkable decrease in the percentage of apoptotic stem cells in the bone marrow </plain></SENT>
<SENT sid="5" pm="."><plain>This preliminary report indicates that infliximab may have an application as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> therapy and warrants further investigation </plain></SENT>
</text></document>